Mitsubishi Tanabe's DPP-4 inhibitor teneligliptin filed in first market
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma (MTP) has made the first regulatory submission worldwide for its DPP-4 inhibitor teneligliptin (MP-513), in Japan for the treatment of type 2 diabetes.